Brief: Newron Pharmaceuticals: Zambon Announces Approval And ARTG Listing Of Safinamide In Australia
30/11/2018 06:02
Nov 30 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* ZAMBON ANNOUNCES APPROVAL AND ARTG LISTING OF SAFINAMIDE
IN
AUSTRALIA FOR TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE
Source text for Eikon: ID:nNDL93cQCB
Further company coverage: NWRN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study